The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Medicine & Life Sciences

• pirfenidone 100%
• Interstitial Lung Diseases 71%
• Rheumatoid Arthritis 53%
• Clinical Trials 42%
• Safety 11%
• Quality of Life 6%
• Connective Tissue Diseases 5%
• Premature Mortality 5%
• Joint Diseases 5%
• Vital Capacity 5%
• United States Food and Drug Administration 4%
• Health Care Costs 4%
• Multicenter Studies 4%
• Therapeutics 4%
• Research Personnel 3%
• Placebos 3%
• Cohort Studies 3%
• Tomography 3%
• Randomized Controlled Trials 3%
• Biomarkers 3%
• Lung 2%
• Pharmaceutical Preparations 2%
• Population 1%